Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Other financing activities (2023 - 2025)

CG Oncology (CGON) has disclosed Other financing activities for 3 consecutive years, with $593000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other financing activities fell 91.34% year-over-year to $593000.0, compared with a TTM value of $316000.0 through Dec 2025, down 90.77%, and an annual FY2025 reading of $316000.0, down 90.77% over the prior year.
  • Other financing activities was $593000.0 for Q4 2025 at CG Oncology, up from $270000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $6.8 million in Q4 2024 and bottomed at -$3.4 million in Q1 2024.
  • Average Other financing activities over 3 years is $928875.0, with a median of $116500.0 recorded in 2024.
  • Peak annual rise in Other financing activities hit 93.15% in 2025, while the deepest fall reached 751.35% in 2025.
  • Year by year, Other financing activities stood at $3.7 million in 2023, then skyrocketed by 85.53% to $6.8 million in 2024, then plummeted by 91.34% to $593000.0 in 2025.
  • Business Quant data shows Other financing activities for CGON at $593000.0 in Q4 2025, $270000.0 in Q3 2025, and -$315000.0 in Q2 2025.